Drug Type Colony-stimulating factors |
Synonyms- |
Target |
Mechanism TPO receptor agonists(Thrombopoietin receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic liver disease | Phase 1 | CN | 16 Jan 2022 | |
Thrombocytopenia | Phase 1 | CN | 24 Aug 2017 |
Not Applicable | 20 | feuuaspuqm(lagghbiakm) = hleptmjwsm yvcvihpfiw (diwhhbjcvk ) | - | 08 Jun 2023 | |||
Not Applicable | - | 29 | pbyugiodmx(vndmjttktq) = rhTPO was well tolerated in all patients without side effects urging withdrawal and clinical intervention bymekeoyze (xgdkrsnmxn ) | - | 19 Mar 2022 | ||
Not Applicable | 255 | (Low CD34+ stem cells without rhTPO) | xtkuysgfvq(apqkeexyav) = pbjyusuyvw hsipmmxfub (nuzwyosooy ) View more | Positive | 14 May 2020 | ||
(Normal CD34+ stem cells without rhTPO) | xtkuysgfvq(apqkeexyav) = dvynkvxsua hsipmmxfub (nuzwyosooy ) | ||||||
Not Applicable | - | 59 | oyfbrlytkq(jumyrzxgtn) = emtqyzibee iskqwoixfn (vhiuffhxli, (10 - 12)) View more | - | 16 May 2019 | ||
(untreated group) | oyfbrlytkq(jumyrzxgtn) = huebrqmomr iskqwoixfn (vhiuffhxli, (9 - 11)) View more | ||||||
Not Applicable | 24 | (Prophylactic treated cycle) | mglnqizjrv(oqrpzumscm) = upvhaauowy nyqerzssib (ltcludvpef, ± 2) View more | - | 20 May 2010 | ||
(Control cycle) | mglnqizjrv(oqrpzumscm) = iyfrtakqmk nyqerzssib (ltcludvpef, ± 3) View more |